LICPIC is part of the AGITG Endorsed Study Model (please click here to find out more)
If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
A Double-Blind Randomised Placebo-Controlled Trial Assessing the Effect of Peri-Operative Intravenous Lignocaine and Post-Operative Lignocaine Neurovascular Plane Infusion on Natural Killer Cell Function in Laparoscopic Colorectal Cancer Surgery.
Lignocaine Infusion in Colorectal Cancer Patient Immune Cells (LICPIC Study)
PURPOSE OF THE STUDY
The body has many ways of fighting off cancer. One way is a type of white blood cell which recognises and destroys cancer cells, these ells are called natural killer (NK) cells. People with cancer who have more effective NK cells may have less spread of their cancer. A local anaesthetic drug called Lignocaine is very commonly used to numb areas of skin or muscle before or during an operation. It has been shown to help the NK cells to destroy cancer cells.
The study aims to find out if giving local anaesthetic, Lignocaine, into your bloodstream during surgery will improve part of your immune system after surgery.
A/Prof Stephen Smith
DETAILED INFORMATION AVAILABLE
More detailed information available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) please click here.
Colorectal Surgical Society of Australia and New Zealand (CSSANZ)
Click here to access the table and view recruitment data on all AGITG open trials:
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.